Trials / Completed
CompletedNCT00250575
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
A 24-week, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.
Detailed description
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clozapine |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2009-12-01
- First posted
- 2005-11-08
- Last updated
- 2016-04-21
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00250575. Inclusion in this directory is not an endorsement.